ESOT Congress, Vienna | Sept 8-11

Results from Plexision’s pharma collaboration to be reported at the European Society for Organ Transplantation Congress, Vienna | September 8-11

Optimizing the effectiveness of a new immnosuppressant requires usage, which is informed by an understanding of individual rejection-risk and response to the drug. This knowledge can facilitate the design of novel regimens based on the new immunosuppressant, and the selection of patients suited for such regimens.

Plexision provides PK/PD services and dose-response modeling as the bases for drug target selection and development of companion diagnostics.

The European Society of Transplantation (ESOT) is a premier organization whose members include healthcare providers involved in the care of transplant patients in Europe and internationally.